to then finish off the tumour. but there are some concerns. it may release bits of cancer in the process of breaking it up, and obviously, the big concern there is if you release cancer cells around the body, then you might end up with the spread of the cancer to other places. i ve not seen any evidence of that happening but it s something we, and i m sure the trial, will watch out carefully for. it s not clear if an immune responses been triggered in peter but a month after his procedure, professor wah was able to show me the results of his treatment. this is an mri before treatment for peter and this is the day after and you can see this area is now totally treated and the dark area represents cancer cell death. does that mean that we are looking at a good outcome for peter, potentially, at the moment? yes, early efficacy has proven to be very promising for him. and we will need to follow him up long term. histosonics is working on an updated version of its machine to sell
to hospitals once they ve secured regulatory approval. we ve developed the platform to be adaptable to almost any part of the body. what we are doing in the liver might be the most challenging. it s deep, it moves and those are potential limitations of what were doing, but we ve overcome those and we feel that everything we do gets easier. there are also early trials, separate from histosonics , investigating whether histotripsy can work on other parts of the body. peter s cancer is now stable, but he still has other tumours in his body and he is waiting to see whether histotripsy stimulates an immune response before exploring other treatment options. i think no matter what the outcome on immune response is, i think it s going to be pretty dramatically life changing anyway, just for the removal of that lesion. knowing that that s gone is a huge relief.
better treat tumours which are small and widespread in vital organs like the liver. us based tech company histosonics is running the most advanced histotripsy trial to date. there s tiny, nanometre sized micro bubbles that naturally exist within tissue, and when we hit a focus point with the ultrasound, it excites those bubbles and those bubbles expand and collapse and they mechanically destroy tissue. patients will awake from their procedure and generally most times not know that they were ever treated. the team is going to be using standard ultrasound to identify where in peter s body the tumour is. then they will use this robotic arm to deliver a much stronger therapeutic type of ultrasound to destroy it. histosonics technology is focused on the liver because tumours there are notoriously hard to treat and survival rates are low. the hope is histotripsy will give inoperable patients like peter
which are small and widespread in vital organs like the liver. us based tech company histosonics is running the most advanced histotripsy trial to date. there stiny, nanometre sized micro bubbles that naturally exist within tissue and when we hit a focus point with the ultrasound, it excites those bubbles and those bubbles expand and collapse and they mechanically destroy tissue. patients will awake from their procedure and generally most times not know thst they were ever treated. the team is going to be using standard ultrasound to identify where in peter s body the tumour is. then they will use this robotic arm to deliver a much stronger therapeutic type of ultrasound to destroy it. histrosonics technology is focused on the liver because tumours there are notoriously hard to treat and survival rates are low. the hope is histotripsy will give inoperable patients like peter better treatment options.
so you could have an example where you use histotripsy to stimulate the immune system and then you come in with the immune activating drugs and they might be able to then finish off the tumour. but there are some concerns. it may release bits of cancer in the process of breaking it up and obviously, the big concern there is if you release cancer cells around the body, then you might end up with the spread of the cancer to other places. i ve not seen any evidence of that happening but it s something we and i m sure the trial will keep an eye out for that. it s not clear if an immune responses been triggered in peter but a month after his procedure, professor wah was able to show me the results of his treatment. this is an mri before treatment for peter and this is the day after and you can see this area is now totally treated and the dark area represents cancer cell death. does that mean that we are looking at a good outcome for peter, potentially, at the moment? yes, early efficacy has